Vijaypd Ceutical Limited (VIJAYPD)
📢 Recent Corporate Announcements
Vijaypd Ceutical Limited has issued the notice for its 2nd Annual General Meeting scheduled for September 30, 2026. Key special resolutions include raising the overall managerial remuneration cap from 11% up to 30% of net profits for FY26-27, and approval of material related party transactions with wholly owned subsidiary Siddharth Drugs Private Limited. Subsequent event disclosures confirm the 100% acquisition of Siddharth Drugs on April 7, 2026, for a consideration of ₹701 Lakhs.
- 2nd Annual General Meeting scheduled for September 30, 2026, at 5:00 PM IST
- Special resolution proposed to raise overall managerial remuneration ceiling from 11% to 30% of net profits for FY26-27
- Managing and Whole-Time Director remuneration cap proposed up to 15% of net profits
- Acquisition of 100% stake in M/s Siddharth Drugs Private Limited completed on April 7, 2026, for ₹701 Lakhs
Vijaypd Ceutical Limited held a Board Meeting on August 29, 2026, approving the Notice and Director's Report for its 2nd Annual General Meeting (AGM) for FY ended March 31, 2026. The Board also appointed M/s. Nikunj Kanabar & Associates as the Scrutinizer for the AGM voting process. Additionally, M/s. Nikunj Kanabar & Associates was appointed as the Secretarial Auditor for FY 2026-27. These decisions are standard annual statutory and governance compliance procedures.
- Board approved the Notice and Directors' Report for the 2nd AGM for the financial year ended March 31, 2026.
- Appointed M/s. Nikunj Kanabar & Associates as Secretarial Auditor for FY 2026-27 on August 29, 2026.
- Appointed M/s. Nikunj Kanabar & Associates as Scrutinizer for conducting the voting process at the 2nd AGM.
- Board meeting commenced at 12:30 pm and concluded at 1:00 pm on August 29, 2026.
Vijaypd Ceutical Limited received an Expression of Interest (EOI) from M/s. Squadron Pharmaceuticals LLP on August 26, 2026. The proposed association is for contract manufacturing of Active Pharmaceutical Ingredients (APIs) targeting export markets. The specific products proposed under the arrangement are Sitagliptin, Apixaban, and Rivaroxaban. Commercial terms and financial impact are yet to be finalized as the discussions remain at an exploratory stage.
- Received EOI from M/s. Squadron Pharmaceuticals LLP for API contract manufacturing
- Covers 3 key pharmaceutical molecules: Sitagliptin, Apixaban, and Rivaroxaban
- Focuses specifically on opportunities in pharmaceutical export markets
- Financial impact not disclosed as the proposal remains at an exploratory stage
Financial Performance
Revenue Growth by Segment
The company operates in a single segment of pharmaceutical trading. Revenue from operations for H1 FY26 stood at INR 5,133.40 Lakhs, representing a 2.01% YoY growth compared to INR 5,032.28 Lakhs in H1 FY25. On a half-yearly basis, revenue grew 2.85% compared to the preceding half-year (H2 FY25) which was INR 4,991.12 Lakhs.
Geographic Revenue Split
Not disclosed in available documents, though the company is headquartered in Mumbai, Maharashtra, and holds MIDC land for factory construction.
Profitability Margins
Gross margins (Revenue minus Purchases and Inventory changes) stood at INR 630.63 Lakhs (12.28% of total income) in H1 FY26. Net Profit Margin for H1 FY26 was 4.68%, a slight improvement from 4.66% in FY25, despite a 18.15% YoY decline in absolute Net Profit from INR 295.11 Lakhs in H1 FY25 to INR 241.54 Lakhs in H1 FY26 due to higher tax provisions.
EBITDA Margin
Operating Profit (before interest, tax, and depreciation) for H1 FY26 was INR 468.31 Lakhs, representing an EBITDA margin of 9.07%. This is a decrease from the 11.66% margin recorded in H1 FY25 (INR 586.85 Lakhs) due to higher employee benefit expenses which rose 103.6% YoY to INR 121.98 Lakhs.
Capital Expenditure
The company has invested INR 53.39 Lakhs in Capital Work-in-Progress as of September 30, 2025, for the construction of a new factory building. Total Property, Plant, and Equipment (PPE) and Intangible assets stand at INR 847.48 Lakhs.
Credit Rating & Borrowing
Total borrowings decreased by 7.9% from INR 2,177.29 Lakhs in March 2025 to INR 2,007.91 Lakhs in September 2025. Finance costs for H1 FY26 were INR 106.12 Lakhs, implying an annualized average borrowing cost of approximately 10.57%.
Operational Drivers
Raw Materials
As a trading entity, the primary cost is 'Stock-in-Trade' (finished pharmaceutical products), which accounted for INR 4,261.57 Lakhs or 88.2% of total expenses in H1 FY26.
Import Sources
Not disclosed in available documents; primarily domestic sourcing for pharmaceutical distribution.
Key Suppliers
Not disclosed in available documents; however, the company acts as a wholesale distributor for various pharmaceutical brands.
Capacity Expansion
The company received MIDC building plan approval and commenced construction of a new factory building on September 6, 2025. Current Capital Work-in-Progress is INR 53.39 Lakhs, up from INR 11.01 Lakhs in March 2025.
Raw Material Costs
Purchase of stock-in-trade decreased by 10.15% YoY from INR 4,743.23 Lakhs in H1 FY25 to INR 4,261.57 Lakhs in H1 FY26, reflecting tighter procurement or shifts in product mix.
Manufacturing Efficiency
Currently a trading-focused model; efficiency is measured by inventory turnover. Inventory turnover ratio (annualized) is approximately 9.3x based on H1 FY26 COGS.
Logistics & Distribution
Distribution and other expenses represented 1.41% of total revenue in H1 FY26, down from 1.55% in H1 FY25.
Strategic Growth
Expected Growth Rate
10-15%
Growth Strategy
Growth will be driven by the acquisition of a 95% stake in Zen Pharmaceuticals (INR 5.97 Cr turnover) for INR 45 Lakhs and the planned acquisition of Siddharth Drugs. Additionally, the transition from pure trading to manufacturing via the new MIDC factory building is expected to improve margins and market reach.
Products & Services
Wholesale distribution of drugs, medicines, and pharmaceutical products.
Brand Portfolio
VijayPD Ceutical (formerly Vijay Pharma).
New Products/Services
Expansion into manufacturing following the completion of the factory building; expected to contribute to revenue post-FY26.
Market Expansion
Strategic focus on expanding the 'Pharma Distribution' footprint through inorganic acquisitions in the Maharashtra region.
Market Share & Ranking
Not disclosed; operates in the highly fragmented pharmaceutical wholesale distribution market.
Strategic Alliances
Signed Letter of Intent (LOI) for the acquisition of Siddharth Drugs Private Limited and completed the acquisition of Zen Pharmaceuticals.
External Factors
Industry Trends
The pharmaceutical distribution industry is shifting toward consolidation and organized players. The company is positioning itself by acquiring smaller firms (Zen Pharmaceuticals) to gain scale and moving toward backward integration into manufacturing.
Competitive Landscape
Competes with numerous unorganized and organized regional pharmaceutical distributors and C&F agents.
Competitive Moat
The company's moat is built on its established distribution network in Mumbai and its recent listing on the NSE Emerge platform (Oct 7, 2025), which provides better access to capital for its M&A-led growth strategy.
Macro Economic Sensitivity
Highly sensitive to healthcare spending and pharmaceutical consumption trends in India.
Consumer Behavior
Increased demand for chronic disease medication and generic drugs is driving higher volumes through wholesale channels.
Geopolitical Risks
Low, as operations are concentrated in the domestic Indian pharmaceutical market.
Regulatory & Governance
Industry Regulations
Subject to Drug and Cosmetics Act regulations, wholesale drug licenses, and MIDC building norms for its new facility.
Environmental Compliance
Not disclosed; will become relevant once the factory construction is completed and manufacturing commences.
Taxation Policy Impact
Effective tax rate for H1 FY26 was 27.77% (INR 92.88 Lakhs tax on INR 334.42 Lakhs PBT).
Legal Contingencies
No material legal contingencies or pending court cases disclosed in the financial notes.
Risk Analysis
Key Uncertainties
Integration risk of acquired entities (Zen Pharmaceuticals and Siddharth Drugs) and potential delays in the construction of the MIDC factory could impact the 10-15% growth target.
Geographic Concentration Risk
High concentration in Mumbai and Maharashtra, with the corporate office and new factory both located in this region.
Third Party Dependencies
High dependency on pharmaceutical manufacturers for supply and credit terms; trade payables stand at INR 253.10 Lakhs.
Technology Obsolescence Risk
Low risk in trading, but requires digital inventory management systems to maintain the current 9.3x turnover ratio.
Credit & Counterparty Risk
Trade receivables of INR 2,322.30 Lakhs are high relative to half-yearly sales, suggesting potential credit risk if collections from retail pharmacies slow down.
